what is the average monthly weight loss on semaglutide for Loss: to Know (2026 Guide) Get after your goal weight
Description
Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
Both end points were assessed from baseline to week 68. In persons with obesity and knee osteoarthritis, once-weekly semaglutide significantly reduced body weight and knee osteoarthritis pain, as compared with placebo. Read the full STEP 9 trial results and Plain Language Summary: #ClinicalTrials #MedicalResearch
Leading up to #ASCO25, Monica Avila, MD, highlights promising research showing GLP-1 drugs may lower the risk of obesity-related cancers, especially in women with diabetes
The molecule contains a modified amino acid sequence derived from the glucagon backbone and includes substitutions designed to improve resistance to enzymatic degradation while preserving receptor binding functionality
Move after meals Even a short walk after eating may support better glucose balance
GLP-1 receptor agonists work by mimicking naturally occurring hormones involved in appetite signaling, digestion, and metabolic processes
